 |
ช่วยแปะย่อๆของคุณ namkati ที่ link ในคห.39 ครับ
http://www.ncbi.nlm.nih.gov/pubmed/15569871?tool=besthealth.bmj.com
Stroke. 2005 Jan;36(1):74-9. Epub 2004 Nov 29.
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
CONCLUSIONS:
This small phase II trial evaluated a wide range of rFVIIa doses in acute ICH and raised no major safety concerns. Larger studies are justified to determine whether rFVIIa can safely and effectively limit ICH growth.
http://www.ncbi.nlm.nih.gov/pubmed/15728810%20?tool=besthealth.bmj.com
Recombinant activated factor VII for acute intracerebral hemorrhage.
N Engl J Med. 2005 Feb 24;352(8):777-85.
CONCLUSIONS:Treatment with rFVIIa within four hours after the onset of intracerebral hemorrhage limits the growth of the hematoma, reduces mortality, and improves functional outcomes at 90 days, despite a small increase in the frequency of thromboembolic adverse events.
ส่วนอันนี้เพิ่มให้ครับ
http://www.ncbi.nlm.nih.gov/pubmed/19821350
Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage.
Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005951.
AUTHORS' CONCLUSIONS:Haemostatic drugs cannot be recommended for the treatment of acute spontaneous ICH in clinical practice, but a large RCT would be justified.
http://www.ncbi.nlm.nih.gov/pubmed/20399668
A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia.
J Clin Neurosci. 2010 Jun;17(6):685-93.
Abstract
Hematoma growth is common in intracerebral hemorrhage (ICH) and is associated with a poor outcome for patients. To evaluate the efficacy and safety of recombinant activated factor VII (rFVIIa) used as a hemostatic agent in patients with ICH without hemophilia, we searched Medline, Scopus, the Cochrane Library, Clinicaltrials.gov and the Stroke Trials Directory. Five randomized controlled trials were selected for analysis. Although rFVIIa can reduce the change in ICH volume, there was no significant difference in mortality, modified Rankin Scale (mRS) score or extended Glasgow Outcome Scale (GOS-E) score in patients treated with rFVIIa or placebo. There was a significant increase in arterial thromboembolic adverse events (TAE) in patients treated with rFVIIa. There was an increase in deep vein thrombosis in patients with spontaneous ICH and traumatic ICH. In conclusion, the use of rFVIIa reduces the growth of the hematoma but does not improve patient survival or functional outcome after ICH; in addition, rFVIIa increases the incidence of arterial TAE.
ไม่แปลไม่วิจารณ์แล้วกันนะครับ ถูก Flu เล่นงานอยู่ กินมาม่าไม่ลง
| จากคุณ |
:
Rockman
|
| เขียนเมื่อ |
:
23 พ.ย. 55 14:58:47
A:61.90.121.204 X: TicketID:353287
|
|
|
|
|
แม่ผมมีเลือดออกในสมอง ทำให้ยกแขนและขา ข้างซ้ายไม่ได้ ผมควรยินยอมให้หมอผ่าตัดสมองดีหรือเปล่าครับ
